Intrauterine Devices at Six Months: Does Patient Age Matter? Results from an Urban Family Medicine Federally Qualified Health Center (FQHC) Network

References

1. 1.↵
   Winnable battles: teen pregnancy. Atlanta (GA): Centers for Disease Control and Prevention; April 2013. Available from: http://www.cdc.gov/winnablebattles/teenpregnancy/index.html. Accessed June 30, 2013.
2. 2.↵
   Fact sheet: unintended pregnancy in the United States. New York: Guttmacher Institute; December 2013. Available from: http://www.guttmacher.org/pubs/FB-Unintended-Pregnancy-US.html. Accessed September 21, 2014.
3. 3.↵
   A sketch of community health centers chart book 2013. Bethesda (MD): National Association of Community Health Centers. Available from: http://www.nachc.com/client/Chartbook2013.pdf. Accessed September 21, 2014.
4. 4.↵
   1. Wood S,
   2. Beeson T,
   3. Bruen B,
   4. et al

   . Scope of family planning services available in federally qualified health centers. Contraception 2014;89:85–90.

   OpenUrlPubMed
5. 5.↵
   1. Beeson T,
   2. Wood S,
   3. Bruen B,
   4. Goldberg DG,
   5. Mead H,
   6. Rosenbaum S

   . Accessibility of long-acting reversible contraceptives (LARCs) in federally qualified health centers (FQHCs). Contraception 2014;89:91–6.

   OpenUrlPubMed
6. 6.↵
   1. Grimes DA

   . Forgettable contraception. Contraception 2009;80:497–9.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group; The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2012;120:983–8.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Finer LB,
   2. Jerman J,
   3. Kavanaugh ML

   . Changes in use of long-acting contraceptive methods in the United States, 2007–2009. Fertil Steril 2012;98:893–7.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Rubin SE,
   2. Davis K,
   3. McKee MD

   . New York City physicians' views of providing long-acting reversible contraception to adolescents. Ann Fam Med 2013;11:130–6.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Michie L,
    2. Cameron ST

    . Improving the uptake of long acting reversible contraception: a review. Minerva Ginecol 2013;65:241–52.

    OpenUrlPubMed
11. 11.↵
    Centers for Disease Control and Prevention (CDC). Contraceptive methods available to patients of office-based physicians and Title X clinics—United States, 2009–2010. MMWR Morb Mortal Wkly Rep 2011;60:1–4.

    OpenUrlPubMed
12. 12.↵
    1. Greenberg KB,
    2. Makino KK,
    3. Coles MS

    . Factors associated with provision of long-acting reversible contraception among adolescent health care providers. J Adolesc Health 2013;52:372–4.

    OpenUrlPubMed
13. 13.↵
    1. Tyler CP,
    2. Whiteman MK,
    3. Zapata LB,
    4. Curtis KM,
    5. Hillis SD,
    6. Marchbanks PA

    . Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 2012;119:762–71.

    OpenUrlPubMed
14. 14.↵
    1. Rubin SE,
    2. Davis K,
    3. McKee MD

    . Providing long-acting reversible contraception to adolescents: what are urban primary care providers thinking? J Adolesc Health 2012;50(2 Suppl):S14–5.

    OpenUrl
15. 15.↵
    1. Kohn JE,
    2. Hacker JG,
    3. Rousselle MA,
    4. Gold M

    . Knowledge and likelihood to recommend intrauterine devices for adolescents among school-based health center providers. J Adolesc Health 2012;51:319–24.

    OpenUrlPubMed
16. 16.↵
    1. Diaz VA,
    2. Hughes N,
    3. Dickerson LM,
    4. Wessell AM,
    5. Carek PJ

    . Clinician knowledge about use of intrauterine devices in adolescents in South Carolina AHEC. Fam Med 2011;43:407–11.

    OpenUrlPubMed
17. 17.↵
    1. Berenson AB,
    2. Tan A,
    3. Hirth JM,
    4. Wilkinson GS

    . Complications and continuation of intrauterine device use among commercially insured teenagers. Obstet Gyneco1 2013;121:951–8.

    OpenUrl
18. 18.↵
    1. Carr S,
    2. Espey E

    . Intrauterine devices and pelvic inflammatory disease among adolescents. J Adolesc Health 2013;52(4 Suppl):S22–8.

    OpenUrl
19. 19.↵
    1. Grunloh DS,
    2. Casner T,
    3. Secura GM,
    4. Peipert JF,
    5. Madden T

    . Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013;122:1214–21.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Alton TM,
    2. Brock GN,
    3. Yang D,
    4. Wilking DA,
    5. Hertweck SP,
    6. Loveless MB

    . Retrospective review of intrauterine device in adolescent and young women. J Pediatr Adolesc Gynecol 2012;25:195–200.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Bayer LL,
    2. Hillard PJA

    . Use of levonorgestrel intrauterine system for medical indications in adolescents. J Adolesc Health 2013;52(4 Suppl):S54–8.

    OpenUrlPubMed
22. 22.↵
    1. Teal SB,
    2. Sheeder J

    . IUD use in adolescent mothers: retention, failure and reasons for discontinuation. Contraception 2012;85:270–4.

    OpenUrlPubMed
23. 23.↵
    Health Resources and Services Administration. The Affordable Care Act and health centers. Washington, DC: US Department of Health and Human Services; 2014. Available from: http://bphc.hrsa.gov/about/healthcenterfactsheet.pdf. Accessed September 21, 2014.
24. 24.↵
    1. Chandra A,
    2. Copen CE,
    3. Stephen EH

    . Infertility and impaired fecundity in the United States, 1982–2010: data from the National Survey of Family Growth. Natl Health Stat Report 2013;(67):1–18, 1 p following 19.
25. 25.↵
    1. Aoun J,
    2. Dines VA,
    3. Stovall DW,
    4. Mete M,
    5. Nelson CB,
    6. Gomez-Lobo V

    . Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 2014;123:585–92.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Garbers S,
    2. Haines-Stephan J,
    3. Lipton Y,
    4. Meserve A,
    5. Spieler L,
    6. Chiasson MA

    . Continuation of copper-containing intrauterine devices at 6 months. Contraception 2013;87:101–6.

    OpenUrlPubMed
27. 27.↵
    1. Folger SG,
    2. Jamieson DJ,
    3. Godfrey EM,
    4. Zapata LB,
    5. Curtis KM

    . Evidence-based guidance on Selected Practice Recommendations for Contraceptive Use: identification of research gaps. Contraception 2013;87:517–23.

    OpenUrlPubMed
28. 28.↵
    1. Bayer LL,
    2. Jensen JT,
    3. Li H,
    4. Nichols MD,
    5. Bednarek PH

    . Adolescent experience with intrauterine device insertion and use: a retrospective cohort study. Contraception 2012;86:443–51.

    OpenUrlPubMed
29. 29.↵
    1. Dickerson LM,
    2. Diaz VA,
    3. Jordon J,
    4. et al

    . Satisfaction, early removal, and side effects associated with long-acting reversible contraception. Fam Med 2013;45:701–7.

    OpenUrlPubMed
30. 30.↵
    2008 Sexually transmitted diseases surveillance. Sexually transmitted diseases in the United States, 2008: National surveillance data for chlamydia, gonorrhea, and syphilis. Atlanta (GA): Control Centers for Disease Control and Prevention; 2009. Available from: http://www.cdc.gov/std/stats08/trends.htm. Accessed September 21, 2014.
31. 31.↵
    1. Markham MR,
    2. Maggio L,
    3. Shah UR,
    4. Sangi-Haghpeykar H,
    5. Raine SP

    . Effects of routine screening for gonorrhea and chlamydia before intrauterine device insertion. Obstet Gynecol 2014;123(Suppl 1):11S.

    OpenUrl
32. 32.↵
    1. Bergin A,
    2. Tristan S,
    3. Terplan M,
    4. Gilliam ML,
    5. Whitaker AK

    . A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception 2012;86:694–7.

    OpenUrlPubMed
33. 33.↵
    1. Rubin SE,
    2. Fletcher J,
    3. Stein T,
    4. Segall-Gutierrez P,
    5. Gold M

    . Determinants of intrauterine contraception provision among US family physicians: a national survey of knowledge, attitudes and practice. Contraception 2011;83:472–8.

    OpenUrlCrossRefPubMed